CES 2026 recap: Morgan Stanley flags ’skyrocketing’ AI demand
This AI-picked telecom is up a whopping +77% in January’s first two sessions
Investors are likely to see this stock as ’next AI power play’: BofA
Futures flat, CES 2026 takes central stage- what’s moving markets
Investing.com -- Generative AI (GenAI) is evolving into a general-purpose technology that could reshape economic growth, productivity, and competitive dynamics across industries over the next decade.
In a Tuesday note to clients, Truist Securities launched coverage on the stocks it believes are shaping “the architecture of the GenAI economy.”
Analyst Arvind Ramnani expects GenAI adoption “to compress the market impact of the last 40 years of enterprise tech into the next 5–10 years,” with AI moving beyond cost savings to directly rewiring how work is done and how companies scale.
Ramnani expects GenAI to automate and augment knowledge work across areas such as coding, design, finance and analysis, driving lower payroll intensity and higher productivity.
He highlights early evidence that workers using GenAI tools are already seeing material productivity gains, while enterprise adoption remains in its early stages due to compliance and organizational frictions rather than lack of value.
“This gap represents latent demand waiting to be unlocked as enterprise workflows and governance frameworks mature,” Ramnani said.
“Furthermore, as enterprises start to see success with a scaled GenAI offerings, we believe that it will lead to a multi-year runway for growth,” he added.
While acknowledging signs of valuation exuberance in parts of the market, Ramnani believes fundamentals are stronger than in prior tech bubbles, arguing that productivity improvements are quantifiable and that investment is largely coming from scaled incumbents rather than fragile startups.
He expects value to migrate toward companies with proprietary data, workflow-embedded platforms and domain-specific applications, rather than commoditized AI capacity.
Against this backdrop, Truist initiated coverage with Buy ratings on seven GenAI-exposed stocks it sees as best positioned for 2026.
1)Palantiris described as a “best-in-class AI asset,” with Ramnani pointing to “material improvement in its momentum driven by the release of AIP (Artificial Intelligence Platform),” which has led to sharply accelerating growth and operating margins moving above 50%.
The analyst viewsPalantiras a key beneficiary of enterprise and government efforts to operationalize GenAI on top of proprietary data sets.
2)TurboTax makerIntuitis seen as combining “durable double-digit growth, expanding margins and a broad AI platform,” with GenAI increasingly visible in product differentiation and financial performance.
Ramnani argues the company’s scale, proprietary data and strategy position it to navigate the GenAI transition despite competition from AI-native entrants.
3)Accenture, meanwhile, is framed as a way to benefit from enterprise modernization “largely driven by GenAI,” supported by its partnerships across the frontier AI ecosystem and a track record of adapting its business model as legacy work is cannibalized.
4)Within digital platforms, Ramnani highlightsDuolingoas an AI beneficiary where GenAI tools are contributing to content generation and new product releases, reinforcing its engagement-led growth model.
5)Lemonadeis also initiated at Buy, with the company embedding AI “across the entire business,” from underwriting to claims and customer service, giving it a structurally lower cost base than traditional insurers, the analyst said.
6)CCC Intelligent Solutions is highlighted as having a “defensible data moat and a highly sticky client base,” supporting steady growth and margin expansion in insurance workflows.
7)Finally,Upstartrounds out the Buy-rated picks. The fintech firm’s core offering is “anchored around GenAI,” using non-traditional data to automate credit decisions and offering what Ramnani calls a levered way to play improving consumer credit conditions.
